With PsyLabs, Psyence BioMed secures GMP ibogaine from sustainable iboga bark, processing 50 kg into ibogaine HCL and Total Alkaloid Extracts for …
With PsyLabs, Psyence BioMed secures GMP ibogaine from sustainable iboga bark, processing 50 kg into ibogaine HCL and Total Alkaloid Extracts for …
Psyence Biomedical Ltd. announced it had established a sustainable supply of high-potency iboga bark from trusted sourcing channels with deep experience in the iboga trade and treatment field through its strategic partner, PsyLabs. This is a significant achievement for the Company as it prepares for the clinical development of ibogaine for substance use disorders and validates its investment in PsyLabs. This collaboration with PsyLabs is an important step in securing a long-term supply ...
NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced it had established a sustainable supply of high-potency iboga bark from trusted sourcing channels ...
HOLLYWOOD, FL – November 18, 2025 – Ibogaine By David Dardashti, a globally recognized leader in psychedelic-assisted therapies, today announced the five-year anniversary of the strategic integration of its specialized Ibogaine “reflection” treatment protocol. Following five years of meticulous data collection and patient monitoring, the clinic reports significant long-term success improvements for patients utilizing this smaller, follow-up ...
Whether through psilocybin, MDMA, ibogaine or future discoveries, the mission is clear: fund the research, pursue the science and ensure America's …